| Technical Name | Discoverydevelopment of novel anti-diabetic drug candidate DBPR211 by antagonizing peripheral CB1 receptors | ||
|---|---|---|---|
| Project Operator | National Health Research Institutes | ||
| Project Host | - | ||
| Summary | DBPR211 is the second generation of CB1 receptor antagonist with peripheral distribution to avoid undesirable central CB1 receptor-induced psychiatric effects as commonly seen in the first generation of CB1 antagonists. DBPR211 is potentselective,it exhibits satisfactory efficacy, pharmacokinetic properties,can be orally absorbed. In obesediabetic mouse models, DBPR211 significa | ||
| Scientific Breakthrough | - | ||
| Industrial Applicability | - | ||
| Keyword | |||